Pharmacologic treatment augmentation in chronic depression “randomized, controlled, double blinded, phase II study”

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512478-86-00

Acronym

Ketamin plus CBASP

Enrollment

Registered

2024-04-10

Start date

2023-07-07

Completion date

Unknown

Last updated

2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis of chronic depression

Brief summary

Depressive symptoms will be assessed by the Montgomery Asberg Depression Rating Scale(MADRS, Schmidtke et al., 1988), a standardized and widely used clinician rating scale. TheMADRS will be conducted by a rater independent of the the treatment team and blind totreatment condition.

Interventions

DRUGIsotonische Kochsalzlösung Fresenius

DRUGInfusionslösung

DRUGKetamin Inresa 2 ml 50 mg/ml Injektionslösung Ketaminhydrochlorid

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Depressive symptoms will be assessed by the Montgomery Asberg Depression Rating Scale(MADRS, Schmidtke et al., 1988), a standardized and widely used clinician rating scale. TheMADRS will be conducted by a rater independent of the the treatment team and blind totreatment condition.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026